Phase 3 Trial to Evaluate Efficacy & Safety of Aficamten (CK-3773274) in oHCM (SEQUOIA-HCM)
Research type
Research Study
Full title
A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
IRAS ID
1005127
Contact name
Lynsey Kennedy
Contact email
Sponsor organisation
Cytokinetics, Inc.
Eudract number
2021-003536-92
Clinicaltrials.gov Identifier
Research summary
The purpose of this study is to determine the effects of CK-3773274 on exercise capacity and general health status of participants with oHCM. The safety and tolerability of CK-3773274 will also be studied.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
22/EM/0083
Date of REC Opinion
25 May 2022
REC opinion
Further Information Favourable Opinion